Nuvation Bio (NUVB) Stock Forecast & Price Target

Compare

711 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NUVB Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Nuvation

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NUVB Stock 12 Month Forecast

Average Price Target

$11.63

▲(98.80% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $11.63 with a high forecast of $17.00 and a low forecast of $9.00. The average price target represents a 98.80% change from the last price of $5.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","4.5":"$4.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.5,9,13.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.96,9.57846153846154,10.196923076923078,10.815384615384616,11.433846153846154,12.052307692307693,12.670769230769231,13.28923076923077,13.907692307692308,14.526153846153846,15.144615384615385,15.763076923076923,16.38153846153846,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.96,9.165384615384616,9.370769230769232,9.576153846153847,9.781538461538462,9.986923076923077,10.192307692307693,10.397692307692308,10.603076923076923,10.80846153846154,11.013846153846155,11.21923076923077,11.424615384615386,{"y":11.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.96,8.963076923076924,8.966153846153848,8.96923076923077,8.972307692307693,8.975384615384616,8.97846153846154,8.981538461538461,8.984615384615385,8.987692307692308,8.990769230769232,8.993846153846153,8.996923076923077,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.66,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.97,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$17.00

Average Price Target$11.63

Lowest Price Target$9.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Soumit Roy

JonesTrading

$10→$12

Buy

105.13%

Upside

Reiterated

01/15/26

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Nuvation Bio (NUVB)

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Nierengarten

Wedbush

$11

Buy

88.03%

Upside

Reiterated

01/13/26

Wedbush Remains a Buy on Nuvation Bio (NUVB)

Mayank Mamtani

B. Riley Securities

$12

Buy

105.13%

Upside

Reiterated

01/13/26

Nuvation Bio shares attractive on weakness, says B. RileyNuvation Bio shares attractive on weakness, says B. Riley

Yaron Werber

TD Cowen

Buy

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB) and Regeneron (NASDAQ: REGN)

Robert Burns

H.C. Wainwright

$18→$17

Buy

190.60%

Upside

Reiterated

01/12/26

Nuvation Bio price target lowered to $17 from $18 at H.C. WainwrightNuvation Bio price target lowered to $17 from $18 at H.C. Wainwright

Leonid Timashev

RBC Capital

$8→$9

Buy

53.85%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Mediwound (NASDAQ: MDWD) and Argenx Se (NASDAQ: ARGX)

Michael Yee

UBS

$10

Hold

70.94%

Upside

Initiated

01/06/26

Nuvation Bio initiated with a Neutral at UBSNuvation Bio initiated with a Neutral at UBS

Kaveri Pohlman

Clear Street

$12

Buy

105.13%

Upside

Reiterated

11/26/25

Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued

Silvan Tuerkcan

Citizens JMP

$8→$10

Buy

70.94%

Upside

Reiterated

11/20/25

Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP

Farzin Haque

Jefferies

$10

Buy

70.94%

Upside

Initiated

09/29/25

Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Soumit Roy

JonesTrading

$10→$12

Buy

105.13%

Upside

Reiterated

01/15/26

Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Nuvation Bio (NUVB)

Gregory Renza

Truist Financial

Buy

―

Reiterated

01/13/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

David Nierengarten

Wedbush

$11

Buy

88.03%

Upside

Reiterated

01/13/26

Wedbush Remains a Buy on Nuvation Bio (NUVB)

Mayank Mamtani

B. Riley Securities

$12

Buy

105.13%

Upside

Reiterated

01/13/26

Nuvation Bio shares attractive on weakness, says B. RileyNuvation Bio shares attractive on weakness, says B. Riley

Yaron Werber

TD Cowen

Buy

―

Reiterated

01/12/26

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB) and Regeneron (NASDAQ: REGN)

Robert Burns

H.C. Wainwright

$18→$17

Buy

190.60%

Upside

Reiterated

01/12/26

Nuvation Bio price target lowered to $17 from $18 at H.C. WainwrightNuvation Bio price target lowered to $17 from $18 at H.C. Wainwright

Leonid Timashev

RBC Capital

$8→$9

Buy

53.85%

Upside

Reiterated

01/08/26

Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NYSE: NUVB), Mediwound (NASDAQ: MDWD) and Argenx Se (NASDAQ: ARGX)

Michael Yee

UBS

$10

Hold

70.94%

Upside

Initiated

01/06/26

Nuvation Bio initiated with a Neutral at UBSNuvation Bio initiated with a Neutral at UBS

Kaveri Pohlman

Clear Street

$12

Buy

105.13%

Upside

Reiterated

11/26/25

Clear Street says thesis intact after Nuvation's NUV-1511 discontinuedClear Street says thesis intact after Nuvation's NUV-1511 discontinued

Silvan Tuerkcan

Citizens JMP

$8→$10

Buy

70.94%

Upside

Reiterated

11/20/25

Nuvation Bio price target raised to $10 from $8 at Citizens JMPNuvation Bio price target raised to $10 from $8 at Citizens JMP

Farzin Haque

Jefferies

$10

Buy

70.94%

Upside

Initiated

09/29/25

Nuvation Bio's Strategic Growth Potential and Promising Pipeline Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvation Bio

3 Months

xxx

Success Rate

12/19 ratings generated profit

Average Return

+21.98%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.16% of your transactions generating a profit, with an average return of +21.98% per trade.

1 Year

David NierengartenWedbush

Success Rate

12/16 ratings generated profit

Average Return

+89.84%

reiterated a buy rating 5 days ago

Copying David Nierengarten's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +89.84% per trade.

2 Years

xxx

Success Rate

17/19 ratings generated profit

Average Return

+122.89%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +122.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVB Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NUVB has received 23 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. NUVB average Analyst price target in the past 3 months is 11.63.

Each month's total comprises the sum of three months' worth of ratings.

NUVB Financial Forecast

NUVB Earnings Forecast

Next quarter’s earnings estimate for NUVB is -$0.09 with a range of -$0.14 to -$0.03. The previous quarter’s EPS was -$0.16. NUVB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Sales Forecast

Next quarter’s sales forecast for NUVB is $38.55M with a range of $19.20M to $51.42M. The previous quarter’s sales results were $13.12M. NUVB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NUVB has Performed in-line its overall industry.

NUVB Stock Forecast FAQ

What is NUVB’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuvation Bio’s 12-month average price target is 11.63.

What is NUVB’s upside potential, based on the analysts’ average price target?

Nuvation Bio has 98.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NUVB a Buy, Sell or Hold?

Nuvation Bio has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Nuvation Bio’s price target?

The average price target for Nuvation Bio is 11.63. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $9.00. The average price target represents 98.80% Increase from the current price of $5.85.

What do analysts say about Nuvation Bio?

Nuvation Bio’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of NUVB?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nuvation Bio (NUVB) Stock Forecast & Price Target

NUVB Analyst Ratings

NUVB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nuvation Bio

NUVB Analyst Recommendation Trends

NUVB Financial Forecast

NUVB Earnings Forecast

NUVB Sales Forecast

NUVB Stock Forecast FAQ

Detailed List of Analyst Forecasts